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Eosinophilic cholecystitis (EC) is a rare inﬂammatory condition of the gallbladder, conﬁrmed by a cellular
inﬁltrate comprised of more than 90% eosinophils in the gallbladder wall on histological examination.
Although the etiology of EC is largely unknown, local autoimmune reactions within the gallbladder wall
to inﬂammatory mediators from distal sites of inﬂammation have been hypothesized.
Talc pleurodesis (TP) is a common clinical procedure used within respiratory medicine. However, it is
associated with activation of systemic acute inﬂammatory responses including an increase in serum
interleukin-8 (IL-8), which is a potent mediator of eosinophil chemotaxis. We report a case of EC
following a TP procedure for persistent, secondary pneumothorax.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
First described in 1949 [1], EC is a rare and poorly understood
inﬂammatory condition of the gallbladder [2], with fewer than 30
cases described in the literature [3]. Clinically indistinguishable
from other causes of cholecystitis, diagnosis is based on histological
examination of the surgical specimen (following cholecystectomy)
and conﬁrmed when cellular inﬁltrate of the gallbladder wall is
composed of more than 90% eosinophils [4]. It can occur with or
without an associated peripheral hypereosinophilia. The etiology of
EC is unknown but links have been hypothesized between local
autoimmune reactions to inﬂammatory mediators, hyper-
eosinophilic syndromes, eosinophilic gastroenteritis, parasitosis,
drugs and medicinal herbs [5,6]. Occasionally, apparent precipi-
tating etiology is absent and idiopathic EC is described [3]. We
report the case of a 52 year old lady who presented with EC
following TP for a persistent, secondary pneumothorax.2. Case report
A 52 year old lady with a background of chronic obstructive
pulmonary disease (COPD), secondary to a heavy smoking history,Talc Pleurodesis; IL-8, Inter-
sar).
Ltd. This is an open access article upresented with severe right upper quadrant pain and nausea.
3 weeks prior to admission, talc slurry pleurodesis was per-
formed to treat a chronic left-sided secondary pneumothorax. The
procedure was well tolerated with no adverse effects documented.
Retrospective review of blood tests prior to pleurodesis demon-
strated normal inﬂammatory markers, no eosinophilia and no he-
patic or biliary abnormalities. Previous CT imaging did not highlight
any hepatic or biliary pathology.
Her past medical history included a total abdominal hysterec-
tomy for menorrhagia and recurrent COPD exacerbations. She
smoked 10 cigarettes a day but did not drink alcohol and denied use
of illicit drugs or herbal supplements. Medications consisted of
salbutamol and Spiriva inhalers, she had no known allergies and
had not received recent courses of antibiotics or steroids. Further-
more, no infective focus was identiﬁed and she had no symptoms
consistent with gastroenteritis. An eosinophil count was normal
(0.3  109/L, Reference Interval < 0.6  109/L), however, a raised
value (1.0  109/L) was noted on routine bloods two weeks post TP.
Bloods on admission are outlined in Table 1. Of note, a mildly
elevated IgE level was recorded (115 IU/mL). Although mildly
elevated, this value is not in keeping with a parasitic process or
Eosinophilic Granulomatosis with Polyangiitis (formally known as
Churg Strauss Syndrome) in which higher IgE levels would be ex-
pected. In addition, whilst both conditions have been linked to EC,
our patient did not demonstrate symptoms consistent with these
diagnoses.
An abdominal CT scan showed an acalculus gallbladder with
inﬂammation consistent with cholecystitis (Fig. 1). Therefore, ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Table of patient blood test results on admission (3 weeks post talc pleurodesis).
Blood test Result Normal reference interval
Bilirubin 5 mmol/L 2e20 mmol/L
ALP 174 U/L 30e150 U/L
GGT 160 U/L 10e35 U/L
ALT 68 U/L 0e30 U/L
AST 53 U/L 10e50 U/L
Haemoglobin 129 g/L 115e155 g/L
WBC 4.8  109/L 4e11  109/L
Platelets 263  109/L 150e400  109/L
Neutrophils 2.9  109/L 1.9e7.5  109/L
Eosinophils 0.3  109/L <0.6  109/L
CRP 8 mg/L <5 mg/L
Renal function tests unremarkable e
IgE 115 IU/mL <100 IU/mL
Fig. 1. CT scan demonstrating thickening of the gallbladder wall (green arrow),
consistent with acute inﬂammation/cholecystitis. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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operative complications were encountered and she was dis-
charged two days later.
Gallbladder histology showed no gallstones and a thickened
wall (5mm) with a dense eosinophilic inﬁltrate (Fig. 2), conﬁrming
a diagnosis of EC. No evidence of epithelial dysplasia or malignancy
was identiﬁed.Fig. 2. Histology slide demonstrating dense eosinophilic inﬁltration of the gallbladder
wall. Magniﬁcation 400. Stain ¼ hematoxylin and eosin stain.3. Discussion
TP is a procedure that can be used to treat persistent pneumo-
thorax [7]. With a high efﬁcacy rate (90%), talc is the agent of choice
for chemical pleurodesis [8]. Predominantly composed of hydrated
magnesium silicate (Mg3Si4O10(OH)2), talc stimulates an intra-
pleural inﬂammatory reaction that causes pleural ﬁbrosis and
scarring, leading to obliteration of the pleural space and prevention
of recurrent pneumothoraces [9]. However, despite its widespread
use, TP is associated with multiple side effects including pain, fever,
dyspnoea and systemic conditions including acute respiratory
distress syndrome [8].
The mechanisms underlying the systemic responses associated
with TP are poorly understood [9]. However, widespread systemic
absorption of talc particles can occur following intra-pleural
administration [8]. Considering the extensive surface area of the
pleural cavity and abundance of lymphatic and vascular vessels, the
hypothesis that talc particle migration plays a role in the genesis of
systemic effects should be considered [10]. Indeed, distant embo-
lization of talc particles to multiple sites, including the lungs, liver,
spleen and brain have been demonstrated in both animal and hu-
man models [8,11,12]. Furthermore, autopsy results have found
systemic talc distribution to every organ of the body, including the
gallbladder [11].
It is thought that after inﬁltration of the pleural cavity with talc
slurry, an acute pleural inﬂammatory response occurs leading to
scarring and ﬁbrosis of the pleura. This process affects the integrity
of the alveolar-capillary barrier, leading to spilling of inﬂammatory
mediators into the lymphatic or blood system. Although, there is no
ﬁrm consensus on the major signaling mechanism for eosinophil
activation [13], TP has been shown to cause an acute systemic
response, including an increase in serum IL-8 [14], a potent medi-
ator of eosinophil chemotaxis [15]. This mechanism could have
occurred in our case, with increased IL-8 levels from pleural cavity
inﬂammation stimulating a systemic response via increased
vascular permeability post pleurodesis [9]. Therefore, in the
absence of a deﬁnitive cause for this presentation of EC, the hy-
pothesized presence of intravascular inﬂammatory mediators post-
pleurodesis could explain the subsequent serum eosinophilia and
eosinophilic gallbladder inﬁltration.
EC has been linked to allergies, parasitic infections, cephalo-
sporin use, hypereosinophilic syndromes and eosinophilic gastro-
enteritis [3]. However, clinical examination, history and
investigation for such causes of EC were unremarkable in our case.
Additionally, no gallstones were identiﬁed during imaging or his-
tology, and whilst acalculous cholecystitis has been linked to
eosinophilic cholecystitis, with EC three times more common in
patients with acalculous cholecystitis than with cholelithiasis, EC
should be considered a separate diagnosis [2]. Furthermore, there
was no clinical evidence of Crohn's disease, sarcoidosis, Sjogren's
syndrome or Polyarteritis Nodosa which have also been implicated
in previously reported acalculus cholecystitis cases [6].
Although no deﬁnitive link can be drawn between TP and EC,
given the rare and uncertain etiology of EC, we believe it is highly
plausible that the two events aremore than coincidental. Due to the
short time period between TP administration and subsequent EC
diagnosis, it seems there is reasonable evidence in the existing
literature to suggest that talc particles or inﬂammatory mediators
from pleural inﬂammation can indeed enter the systemic circula-
tion and stimulate eosinophilic activation with subsequent end-
organ deposition. Consequently, we would like to highlight this
case and the potential risk of eosinophilic cholecystitis post TP to
inform future practice.
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